Hints and tips:
...“It is also hard to establish ill intentions behind the irregular accounting of Samsung Biologics,” it added....
...They would probably focus on extending the company’s dominance in computer chips as well as boosting its 5G business and artificial intelligence technologies....
...As part of a diplomatic charm offensive, China has pledged deliveries of its four leading Covid-19 vaccines — two developed by Sinopharm, one by Beijing-based Sinovac and another from CanSino Biologics —...
...Sinopharm is developing a second Covid-19 vaccine while Sinovac and CanSino Biologics, two other Chinese pharmaceutical companies, are also working to manufacture a jab....
...The company has previously denied all wrongdoing related to the case....
...In December, eight employees from Samsung companies were found guilty of destroying evidence linked to the investigation. Samsung BioLogics has disputed the claims of accounting fraud....
...Samsung BioLogics did not immediately comment on Monday. The company has disputed the claims of accounting fraud. Samsung Electronics declined to comment....
...As a result, the company’s valuation of Samsung Bioepis jumped 18 times to nearly $4.5bn....
...However, the latest series of arrests and raids has raised fresh concerns that the technology group has not changed despite its repeated pledges to improve corporate governance ethics....
...Shares in Samsung BioLogics slumped nearly 8 per cent on Wednesday after local media reported that the company would be hit with disciplinary action related to alleged accounting violations....
...The tie-up with Takeda signals the company is proceeding with a long-expected shift into novel biologic drugs. Samsung declined to reveal details of the “risk-sharing partnership”....
...Biologics are a relatively new branch of medicine, with the products being isolated from a variety of natural sources or produced by biotechnology and other advanced technologies, according to the US Food...
...Samsung Biologics is more than 97 per cent-owned by Samsung Electronics and Samsung C&T, the group’s de facto holding company....
...The fourth-ranked mutual fund, the Oppenheimer International Small Company fund, was also overweight in healthcare technology companies, according to its manager, Rezo Kanovich....
...From ships to smartphones, the country’s manufacturing groups have driven extraordinary economic growth over the past 50 years by investing aggressively to mimic technology pioneered in Japan, the US and...
...The new company will also be the majority shareholder of Samsung Biologics, producer of the biopharmaceutical drugs that Samsung views as a long-term growth area....
...Venture capitalists and specialist investors back early-stage innovative companies as they grow and flourish....
...Last year it announced new investment of Won301bn in the lossmaking Samsung Biologics, which manufactures drugs for pharmaceutical groups....
...It has been bleeding market share as homegrown companies – many deploying suspiciously similar technology – have grabbed sales....
...The non-executive chairman of Green Biologics is Andrew Rickman, founder and chief executive of Bookham, the communications technology company, now known as Oclaro after a merger with Avanex last year....
...The company has started advanced clinical trials of OncoVex in 80 hospitals around the world and if these are completed successfully, it aims to file for a biologics licence from the Food and Drug Administration...
...The company is building a new hydraulic excavator facility in Wujiang that aims to start production in 2012, and has plans fora new large engine factory opening in Tianjin in2013 and an expansion ofits Xuzhou...
...“Japanese companies are chasing these human antibody-type drugs because they feel they’re behind some of the US and European pharmaceutical companies in this technology.”...
...Shares in Xugong Science and Technology, the group’s listed vehicle, were suspended on the Shenzhen stock exchange yesterday pending an announcement....
...Observers said a takeover would jump-start GSK’s move into biologics and it could make big cost savings....
International Edition